Gender-Specific Behaviour in Obesity Stages I-II: Imbalance of Aminothiol Status and Adipomyokine Profile in Subjects with Different Insulin Resistance Severity
Table 1
Anthropometric and clinical characteristics between gender.
Female
Male
Age (years)
59 [57-64]
59 [55-63]
0.389
BMI
33 [32-35]
35 [32-37]
0.149
HOMA index
2.53 [1.80-5.11]
3.41 [2.37-5.53]
0.348
Glucose (mg/dL)
95 [90-110]
98 [95-107]
0.662
Glycated haemoglobin (mmol/mol)
37 [35-41]
36 [35-39]
0.334
Insulin (μU/mL)
11.8 [7.8-18.8]
13.8 [10.1-21.1]
0.325
AST (U/L)
18 [16-22]
20 [18-26]
0.123
ALT (U/L)
18 [14-26]
21 [18-30]
0.087
HDL cholesterol (mg/dL)
56 [51-65]
44 [38-51]
<0.001
LDL cholesterol (mg/dL)
133 [113-150]
120 [108-144]
0.204
Triglycerides (mg/dL)
100 [81-121]
110 [84-145]
0.391
Visceral adipose index
3.39 [2.50-4.53]
3.50 [2.52-4.92]
0.830
Cardiovascular risk factors
Smoking habit, (%)
2 (7%)
7 (24%)
0.076
Hypertension, (%)
13 (42%)
19 (66%)
0.077
Dyslipidemia, (%)
12 (39%)
10 (35%)
0.793
Drugs and supplements
Betablockers, (%)
3 (10%)
4 (14%)
0.702
ACE-inhibitors or angiotensin receptor blockers, (%)
8 (26%)
13 (45%)
0.176
Statins, (%)
5 (16%)
2 (7%)
0.426
Vitamin D supplementation, (%)
5 (16%)
0 (0%)
0.053
Data are expressed as median and interquartile range. HOMA: homeostasis model assessment.
